Inhibition of FAK prevents blister formation in the neonatal mouse model of pemphigus vulgaris.
Pemphigus vulgaris (PV) is an autoimmune blistering skin disease characterized by suprabasal acantholysis and by autoantibodies against desmoglein 3 localized on desmosomes. In addition, caspases also seem to participate in this blistering disease. Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase involved in cytoskeleton remodelling and formation and disassembly of cell adhesion structures. We have previously demonstrated that HER (human epidermal growth factor receptor related) isoforms, Src (Rous sarcoma) and mammalian target of rapamycin (mTOR), three molecules implicated in signalling processes, take part in suprabasal acantholysis and apoptosis induced by PV-IgG in a mouse model. Our aim was to investigate whether upregulation of FAK is implicated in the development of PV lesions. Herein, using a mouse model, PV-IgG administration showed an increased level of FAK phosphorylated on 397 and 925 tyrosine residues in the basal layer of epidermis. When mice were pretreated with a FAK inhibitor (FI), the acantholysis of the basal layer of epidermis was absent. More interestingly, we observed that phosphorylated FAK (Y397/925) decreased when HER isoforms, Src, mTOR and pan-caspases inhibitors were employed before PV-IgG administration. In addition, pretreatment with the FI before PV-IgG injection prevented the changes in both Bax and Bcl-2 expression and caspase-9 and caspase-3 activities induced by PV-IgG. Finally, FI reduced the expression of phosphorylated Src and mTOR in the basal cells of epidermis. In conclusion, our data reveal a novel role of phosphorylated FAK (Y397/925) in PV development involving HER isoforms, Src and mTOR kinases.
Department of Dermatology, School of Medicine, University Clinic of Navarra, University of Navarra, Navarra, Spain.
María P
MP
Gil
Teresa
T
Modol
Agustín
A
España
María J
MJ
López-Zabalza
D000051:Acantholysis / Q000517:prevention & control; D000818:Animals; D000831:Animals, Newborn; D001768:Blister / Q000517:prevention & control; D061945:Caspase Inhibitors; D004195:Disease Models, Animal; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D051416:Focal Adhesion Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007116:Immunization, Passive; D007074:Immunoglobulin G / Q000008:administration & dosage; D051379:Mice; D008810:Mice, Inbred C57BL; D008954:Models, Biological; D010392:Pemphigus / Q000201:enzymology / Q000276:immunology / Q000517:prevention & control*; D010766:Phosphorylation; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D014443:Tyrosine / Q000737:chemistry; D019061:src-Family Kinases / Q000037:antagonists & inhibitors
D061945:Caspase Inhibitors; D007074:Immunoglobulin G; D047428:Protein Kinase Inhibitors; D014443:Tyrosine; C546843:mTOR protein, mouse; C541485:EGFR protein, mouse; D066246:ErbB Receptors; D051416:Focal Adhesion Protein-Tyrosine Kinases; D019061:src-Family Kinases; D058570:TOR Serine-Threonine Kinases